Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 522 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Viread Clear all

Conditions: HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: HIV Infections
Interventions: BMS-955176, Atazanavir (ATV), Ritonavir (RTV), Dolutegravir (DTG), Tenofovir (TDF); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Beverly Hills, California • Los Angeles, California • Palm Springs, California + 13 more

Conditions: Chronic Hepatitis B
Interventions: Tenofovir DF, FTC, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions: TFV/LNG IVR, Placebo; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: HIV
Interventions: Raltegravir, Efavirenz; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis B, Chronic
Interventions: Tenofovir Alafenamide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Palo Alto, California • San Jose, California

Conditions: Healthy Volunteer, HIV Prevention
Interventions: tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 79
States / cities: Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more

Conditions: HIV
Interventions: Tenofovir intravaginal ring, Truvada; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, COBI, ATV, DRV, NRTI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more

Conditions: HIV Infection
Interventions: Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Hepatitis B, Chronic
Interventions: peginterferon alfa-2a [Pegasys], tenofovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Miami, Florida • Honolulu, Hawaii • New York, New York + 3 more

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 27
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 20 more

Conditions: HIV-1
Interventions: F/TAF, 3rd ARV agent, Boosted PIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more

Conditions: Hiv Prevention, Pre-Exposure Prophylaxis (PrEP)
Interventions: Truvada; Drug
Lead sponsor: CAN Community Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Lake Worth, Florida • Miami Beach, Florida + 2 more

Conditions: Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
Interventions: TLC-ART; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV-1-infection
Interventions: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 38
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: HIV, Violence, Gender-Based, Pre-Exposure Prophylaxis
Interventions: Individual PrEP Decision Aid, CDC PrEP Video, Shared PrEP Decision Aid; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV/AIDS, Substance Use Disorders, Adherence, Medication
Interventions: Digital pill, Truvada; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boylston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: HIV Infections
Interventions: Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 16 Years and older
Enrollment: 1,864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 30 more

Conditions: Medication Adherence, HIV Prevention
Interventions: Tenofovir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Evaluation of Albuminuria HIV-Infected Patients

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)

First in Human Study of TLC-ART 101 (ACTU 2001)

Study of Novel Antiretrovirals in Participants With HIV-1

Development and Evaluation of a PrEP Decision Aid for Women Seeking Domestic Violence Services in Baltimore

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Single Dose Truvada Study